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https://doi.org/10.1016/j.celrep.2020.107905SUMMARYCross-presentation of antigens by dendritic cells (DCs) is critical for initiation of anti-tumor immune re-
sponses. Yet, key steps involved in trafficking of antigens taken up by DCs remain incompletely understood.
Here, we screen 700 US Food and Drug Administration (FDA)-approved drugs and identify 37 enhancers of
antigen import from endolysosomes into the cytosol. To reveal their mechanism of action, we generate pro-
teomic organellar maps of control and drug-treated DCs (focusing on two compounds, prazosin and tamox-
ifen). By combining organellar mapping, quantitative proteomics, and microscopy, we conclude that import
enhancers undergo lysosomal trapping leading tomembrane permeation and antigen release. Enhancing an-
tigen import facilitates cross-presentation of soluble and cell-associated antigens. Systemic administration
of prazosin leads to reduced growth of MC38 tumors and to a synergistic effect with checkpoint immuno-
therapy in a melanoma model. Thus, inefficient antigen import into the cytosol limits antigen cross-presen-
tation, restraining the potency of anti-tumor immune responses and efficacy of checkpoint blockers.INTRODUCTION
Accumulation of mutations in cancer is a key factor during dis-
ease progression, yet, it can also render cancer cells vulnerable
to cytotoxic T cells (CTLs). T cell-mediated anti-tumor immune
responses are primarily initiated by type 1 conventional dendritic
cells (cDC1s) (Bo¨ttcher and Reis e Sousa, 2018). Although these
immune responses can in principle prevent or restrict tumor
growth, they are usually not nearly as potent as responses
against pathogens. In recent years, checkpoint inhibitors
emerged as a promising tool to enhance anti-tumor immunity
and were effective in providing long-lasting remissions. Never-
theless, their efficacy is largely dependent on pre-existing immu-
nity, and the benefits are only seen in a fraction of patients (Crit-
tenden et al., 2018). Therefore, a better understanding of the
mechanisms and rate-limiting steps involved in priming of naive
tumor-specific T cells will be critical for improving immunothera-
peutic strategies.
Efficient priming relies on the delivery of three signals to naive
T cells: signal 1, relevant antigen (e.g., a mutated peptide) pre-
sented in the context of major histocompatibility complex
(MHC) class I; signal 2, co-stimulatory molecules expressed by
antigenpresenting cells (APCs); and signal 3, cytokines,which ul-This is an open access article undtimately determine whether the response will lead to immunity or
tolerance. Many approaches have been explored to deliver
appropriate signals 2 and3, including stimulatingDCsmaturation
with a variety of Toll-like receptor (TLR) agonists (e.g., poly(I:C) or
CpG) or growth factors (e.g., FLT3L) (Brunner et al., 2000; Ham-
merich et al., 2019; Salmon et al., 2016; Sa´nchez-Paulete et al.,
2018). However, increasing the efficiency of presentation of tu-
mor antigens on MHC class I has proven more challenging.
Tumor antigens are presented by APCs via a process termed
cross-presentation. Cross-presentation involves endocytic up-
take of exogenous proteins followed by generation of short pep-
tides that can be loaded onto MHC class I. Two models have
been proposed to describe where peptide generation takes
place (reviewed in Gros and Amigorena, 2019). In the vacuolar
model, peptides are generated by endolysosomal proteases (pri-
marily cathepsins) and directly loaded onto MHC class I (Shen
et al., 2004). In the cytosolic model, antigens are imported into
the cytosol, processed by the proteasome, and delivered into
the lumen of MHC class I-containing compartments via the
TAP transporter (Ackerman et al., 2003; Guermonprez et al.,
2003; Kovacsovics-Bankowski and Rock, 1995). Considering
differences in cleavage-specificities among the different prote-
ases, the cytosolic model provides an attractive explanation ofCell Reports 32, 107905, July 14, 2020 ª 2020 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Small Molecule Screen to Identify Enhancers of Antigen Import into the Cytosol
(A) Schematic representation of the b-lactamase assay used to monitor the efficiency of antigen import into the cytosol. MutuDCs were fed with b-lactamase for
3 h followed by 2 h incubation with small molecules (at 37C). CCF4 loading was performed at room temperature for 1 h, and followed by 16 h incubation at RT to
increase the sensitivity of the assay (Zlokarnik et al., 1998). Change in CCF4 fluorescence was monitored by flow cytometry.
(B) Differential effects of ERAD inhibitors on antigen import into the cytosol. Representative flow cytometry data for selected ERAD inhibitors and quantification of
the fold change in antigen import relative to DMSO controls. IMP, importazole; EerI, Eeyarestatin I. Means ± SE (dots represents data from independent ex-
periments).
(legend continued on next page)






OPEN ACCESShow APCs would generate peptides similar to those presented
by target cells, where the majority of epitopes is also generated
by proteasomes. Both TAP- and immunoproteasome-deficient
mice are defective in cross-presentation (Palmowski et al.,
2006; Rock and Shen, 2005), but whether these effects are
indeed due to specific inhibition of cross-presentation, and
whether the cytosolic pathway is dominant in vivo, still requires
verification. Similarly, mechanistic details of endosome-to-
cytosol transport have remained elusive.
Irrespective of the precise mechanism, the importance of
cross-presentation in initiation of anti-tumor responses has
now been demonstrated in a variety of mouse models. cDC1s
appear to bemost efficient cross-presenters in vivo and Batf3/
mice that lack cDC1s, do not mount efficient T cell responses
(Hildner et al., 2008). In mice with a Wdfy4 deletion (Theisen
et al., 2018) or a DC-specific knockout of Sec22b (Alloatti
et al., 2017), cDC1s are present but deficient in the ability to
cross-present. Both models are unable to prime naive T cells
against tumor-associated antigens and fail to control tumor
growth. Similar to cDC1-deficient mice (Sa´nchez-Paulete et al.,
2016), Sec22b knockouts are also resistant to treatment with
checkpoint inhibitors. These data argue for an important role of
cross-presentation in anti-tumor immunity. Indeed, delivering tu-
mor antigens to cross-presenting cells (e.g., via antibody-anti-
gen conjugates), has been effective in promoting CTL responses
(Bonifaz et al., 2002; Caminschi et al., 2008; Sancho et al., 2008).
In the clinic, vaccination with long peptides comprising neoepi-
topes has also been successfully used to boost generation of tu-
mor-specific T cells (Ott et al., 2017). These approaches of
boosting antigen presentation are, however, costly to implement
as they require prior identification of cancer neoantigens (e.g.,
through next generation sequencing of tumor samples).
Here, we present a strategy for enhancing efficiency of T cell
priming by facilitating antigen presentation by DCs. Our study
was based on the hypothesis that import of internalized antigens
into the cytosol might be limiting for the efficiency of cross-pre-
sentation. With this in mind, we set up an assay to screen a li-
brary of over 700 US Food and Drug Administration (FDA)-
approved compounds to identify enhancers of antigen import.
We demonstrated that these molecules indeed facilitated
cross-presentation of both soluble and cell-associated antigens.(C) Quality control of the FDA library screen. The histograms show distribution o
control (all wells across the ten 96-well plates).
(D) Results from the FDA library screen. Fold changes in b-lactamase import for th
selected for the secondary screen (highlighted with the red box).
(E) Examples of the flow cytometry profiles in the antigen import assay for selec
(F) Results from the secondary screen of 37 compounds (and two control com
centrations in two independent experiments. EC50 values (concentration required
Information about chemical classes and candidate targets was obtained from th
versus non-active compounds are represented with colored squares. The enrich
Fisher’s exact test.
(G) Analysis of gene and protein expression in CD8+ cDC1s. mRNA expression dat
www.Immgen.org database (GEO: GSE109125), and whole cell proteomic abund
were detected by proteomics (blue dots) and selected markers highly expressed
proteins detected in whole cell MutuDC proteome are available via the web resour
proteins not detected by proteomics. Targets enriched in the group of active vers
targets of the three active quinazolinamines (Adra1b for prazosin, Adra1a for dox
See also Figures S1 and S2 and Data S1 and S2.To evaluate the biological activity of two import enhancers, pra-
zosin and tamoxifen, we generated comprehensive proteomics-
based organellar maps from treated and untreated cells. We es-
tablished that our most potent compound, prazosin, has a highly
specific effect on endolysosomal membrane permeability. This
encouraged us to pursue in vivo studies, where we demon-
strated that systemic administration of prazosin leads to better
control of tumor growth and synergizes with checkpoint-based
anti-tumor immunotherapy.
RESULTS
Selected Endoplasmic Reticulum-Associated Protein
Degradation (ERAD) Inhibitors Enhance Antigen Import
ERAD machinery has been proposed to play a key role in import
of antigens from endosomes and phagosomes into the cytosol
(Giodini and Cresswell, 2008; Imai et al., 2005; Zehner et al.,
2015). Recently, however, we demonstrated that mycolactone,
a potent inhibitor of Sec61 (a candidate ERAD translocon),
does not inhibit antigen import (Grotzke et al., 2017). Here, we
initially employed a pharmacological approach to evaluate the
contribution of other ERAD components to antigen import. We
selected a range of ERAD inhibitors and tested them using a
b-lactamase-based antigen import assay (Figure 1A) (modified
from Cebrian et al., 2011). As a model system, we used the cell
line MutuDC, which phenotypically corresponds to splenic
cDC1s (FuertesMarraco et al., 2012) (see also Figure 1G). To pre-
vent tested compounds fromaffecting antigen uptake, wepulsed
MutuDCs with b-lactamase for 3 h and subsequently treated
them with the different inhibitors for 2 h. To detect b-lactamase
translocation into the cytosol, we loaded the cells with a cytosolic
b-lactamase substrate, CCF4. When b-lactamase enters the
cytosol, it cleaves theb-lactam ring in theCCF4anddisrupts fluo-
rescence resonance energy transfer (FRET) between its two sub-
unitscausingashift in fluorescence fromgreen toblue (Figure1A).
Wemonitored this change in fluorescenceby flowcytometry (Fig-
ure 1B). The two compounds that target the ubiquitin pathway,
PR-619 and Eeyarestatin I (EerI), inhibited antigen import
(Figure 1B, consistent with previous data) (Grotzke et al., 2017;
Zehner et al., 2015). Unexpectedly, a p97 inhibitor, DbeQ, and
a b-importin inhibitor, importazole, enhanced antigen importf fold changes in the efficiency of antigen import (relative to DMSO) for each
e 786 tested drugs. The screen was performed once, and 37 compounds were
ted active and non-active compounds.
pounds, not active in the primary screen). Each drug was tested at five con-
for 50% of maximal activity) values were calculates as described in Figure S2.
e DrugBank database. The classes and targets enriched in the group of active
ment of targets for hits (compared to the entire library) was calculated using
a (RNA sequencing [RNA-seq]) for CD8+ splenic DCswas downloaded from the
ance data were generated bymass spectrometry fromMutuDCs. 7427 proteins
in cDC1s are highlighted with large blue circles. Absolute copy numbers for all
ce (http://dc-biology.mrc-lmb.cam.ac.uk). The lower panel (gray dots) includes
us non-active compounds are highlighted (Esr1, Drd2, and Slc6a4), as well as
azosin, and Egfr for gefitinib).
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OPEN ACCESS(Figures 1BandS1). This effectwas not recapitulatedwith amore
potent p97 inhibitor, NMS-873, suggesting it might be due to off-
target activity.Hence, although thesedata highlight the role of the
ubiquitin system in antigen import, they did not provide evidence
supporting the role of other ERAD components. The dramatic
enhancement of antigen import observed with two of the com-
pounds suggests that antigen import is relatively inefficient, and
that it may be rate-limiting for cross-presentation.
b-Lactamase-Based Screen for Enhancers of Antigen
Import
Enhancement of antigen import by DbeQ and importazole estab-
lished a proof of concept that this process can be pharmacolog-
icallymanipulated and prompted us to develop a screen for small
molecule import enhancers. We performed the screen in Mu-
tuDCs using the b-lactamase-based antigen import assay and
a library of 786 FDA-approved drugs (Data S1). DbeQ and PR-
619 were used as controls on each plate to track data quality
(Figure 1C). We selected 37 drugs that increased antigen import
at least 2-fold in the primary screen for follow up (Figures 1D and
1E). Two non-active compounds were also included as addi-
tional negative controls (fosfomycin and thioguanine). 32 out of
the 37 compounds exhibited a dose-dependent effect in the sec-
ondary screen (86% validation rate, 4% hit rate) (Figures 1F and
S2). They included three classes of chemically related com-
pounds: quinazolinamines (prazosin, doxazosin, and gefitinib),
stilbenes (clomiphene, raloxifene, tamoxifen, and toremifene),
and phenothiazines (chlorpromazine, fluphenazine, perphena-
zine, thioridazine, and trifluoperazine) (Figures 1F and S1).
To understand the mechanism of antigen import enhance-
ment, we first searched for common targets among the active
compounds. Using the DrugBank database (Law et al., 2014),
we identified previously described targets for 714 of the com-
pounds present in the FDA library. Three of these targets were
significantly enriched among active versus non-active com-
pounds: estrogen receptor (Esr1), dopaminergic receptor
(Drd2), and serotonin transporter (Slc6a4) (Figure 1F, lower
panel). However, none of these three proteins is actually ex-
pressed in CD8+ cDC1s according to Immunological Genome
Project expression data (Yoshida et al., 2019); they are also
not present among the 7,427 proteins we detected in MutuDC
by proteomics (Figure 1G; Data S2). Considering that out of 11
estrogen receptor modulators present in the library, antigen
enhancement was only observed for inhibitors from the stilbene
family, the enrichment appeared to be linked to the structure of
these compounds, rather than to the inhibition of known targets.
Similarly, no protein and only trace mRNA were detected for tar-
gets of themost potent class of enhancers identified, quinazolin-
amines (Adra1, Adra2, and Egfr). Interestingly, DbeQ and impor-
tazole also belong to the quinazolinamine family; hence, half of
the ten quinazolinamine derivatives tested in this study facilitated
import of internalized antigens, despite being marketed as inhib-
itors of different targets.
Organellar Maps to Determine Biological Activity of
Small Molecules in DCs
A variety of ‘‘hidden phenotypes’’ and promiscuous effects have
been observed for numerous clinically approved drugs (Mac-4 Cell Reports 32, 107905, July 14, 2020Donald et al., 2006). These additional phenotypes can often be
beneficial for novel therapeutic indications, yet there are few ap-
proaches to detect the cellular effects of a compound in an un-
biased manner. To characterize the mechanism of antigen
import enhancement, we developed a generic strategy to eval-
uate the biological activity of pharmacological compounds
through comparative spatial proteomics (Figure 2A). Many, if
not most, cell biological processes are accompanied by protein
subcellular localization changes (Lundberg and Borner, 2019;
Borner, 2020). Hence, we adapted our previously developed
method for generating organellar maps to pinpoint the subcellu-
lar localizations of thousands of proteins in a single experiment
(Itzhak et al., 2016, 2017, 2019). The comparison of organellar
maps made under different physiological conditions allows the
capture of drug induced protein translocations (Itzhak et al.,
2016, 2017) and thus provides a universal and scalable tool for
inferences about cellular responses and drug targets.
To generate organellar maps, we separated post-nuclear su-
pernatants from MutuDCs into five pellets obtained by differen-
tial centrifugation (Figure 2A). Each pellet was mixed 1:1 with a
SILAC heavy ‘‘reference’’ membrane fraction, and the samples
were analyzed by mass spectrometry (MS). To generate abun-
dance profiles, we calculated the heavy-to-light ratio for each
protein in each fraction. Using organellar markers we previously
established for HeLa cells (Itzhak et al., 2016), we confirmed
clustering of proteins from different organelles (e.g., lysosome,
peroxisome, and mitochondria) and protein complexes (e.g.,
proteasome and CCR4-NOT complex) (Figures 2B and 2C).
These maps cover over 2,000 proteins expressed in DCs and
can be mined for protein subcellular localization, absolute abun-
dance (copy numbers and cellular concentrations), as well as
nearest neighbors (i.e., potential interaction partners) via a web
resource (http://dc-biology.mrc-lmb.cam.ac.uk; Data S2).
We focused on two import enhancers from different chemical
classes, prazosin (quinazolinamine) and tamoxifen (stilbene). To
investigate their effects on organellar dynamics, we prepared
maps from drug or vehicle-treated MutuDCs in biological dupli-
cates (six maps in total; Data S3). To detect significant protein
translocations, maps of control and drug-treated cells were
compared using MR (movement and reproducibility) plot anal-
ysis (Figures 3A and S3). Tamoxifen treatment led to spatial rear-
rangements of 56 proteins in MutuDCs, whereas prazosin
affected only 33 proteins. The majority of prazosin hits (27/33)
mapped to the lysosomal compartment (Figure 3B). These hits
comprised 23 out of 24 detected soluble lysosomal enzymes
(e.g., cathepsins) as well as three transmembrane proteins.
Out of 13 proteins shifting with both drug treatments, 12 also
mapped to the lysosome (for other lysosomal proteins, the
movement [M] scores in the tamoxifen sample were just below
the threshold). Other proteins that shifted upon tamoxifen treat-
ment included components of COPI vesicles, stress granules
(e.g., Caprin1 and G3bp1), or CCR4-NOT complex (Figure 3B;
Data S3). Thus, in dendritic cells, tamoxifen has pleiotropic ef-
fects and prazosin is highly specific, but there is a common effect
of both compounds on lysosomal proteins.
We went on to analyze the overall behavior of lysosomal pro-
teins detected in MutuDCs in more detail. While the majority of
soluble lysosomal proteins had high M scores (shift to the right
A B
C
Figure 2. Organellar Mapping in Dendritic Cells
(A) Schematic representation of the fractionation profiling approach for making organellar maps. Metabolically labeled (SILAC heavy—vehicle-treated and light—
vehicle- or drug-treated) MutuDCs are lysed mechanically. Post-nuclear supernatant from light labeled cells is subjected to a series of differential centrifugation
steps to separate organelles partially. In parallel, post-nuclear supernatant from heavy labeled cells is pelleted at high speed to obtain a reference fraction, which
is spiked into each of the light fractions. Quantitative mass spectrometry allows the accurate determination of abundance distribution profiles across the light
subfractions for individual proteins. Proteins associated with the same organelle have similar profiles, and different organelles have distinct profiles. Principal
component analysis is used to visualize organellar clusters.
(B) Examples of the log2 heavy/light ratios for proteins in selected organelles and protein complexes from vehicle treated MutuDCs (mean ± 95% confidence
interval [CI]).
(C) Organellar maps of MutuDCs visualized by principal component analysis. The first two principal components account for >90% of the variability in the data.
Marker proteins of various organelles and known protein complexes are shown with colored circles; density gradients for proteins in each cluster are also
highlighted.
See also Data S2.
Resource
ll
OPEN ACCESSof the MR plot), lysosomal transmembrane proteins show little or
no translocation (Figure 3C). This difference in behavior of solu-
ble and transmembrane proteins suggests that lysosomal con-
tents are either secreted into the extracellular space or leaked
into the cytosol.
Prazosin and Tamoxifen Induce Lysosome Permeability
To determine whether lysosomal contents in prazosin- and
tamoxifen-treated cells are secreted or leaked, we performed
quantitative proteomic analyses of whole cell extracts and cyto-
solic fractions (Data S3). We observed significantly elevatedlevels of lysosomal enzymes in the cytosol of prazosin and
tamoxifen-treated MutuDCs relative to control cells (Figure 4A).
Because the levels of these proteins were not changed in whole
cell proteome (Figures 4A and S4), we concluded that both pra-
zosin and tamoxifen facilitate lysosomal leakage. Similar to what
we observed using organellar maps, the prazosin effect is mostly
restricted to lysosomal proteins, whereas tamoxifen affects a
larger and more diverse set of proteins.
To rule out that the observed lysosomal leakagewascausedby
increased compartment fragility and enhanced rupture during
cell fractionation, we tested permeability of endolysosomalCell Reports 32, 107905, July 14, 2020 5
(legend on next page)






OPEN ACCESScompartments in live cells. To this end, we used galectin-3-YFP
probe and video microscopy. Galectin-3 is a cytosolic protein
that associates with the carbohydrates on the luminal side
of the endolysosomal compartments when membranes are
damaged (Thurston et al., 2012). In control cells, galectin-3 signal
is diffuse, and galectin-3-positive structures are rarely observed
(Figure 4B; Video S1). Following addition of prazosin, however,
there are frequent bursts of galectin-3-YFP recruitment to vesic-
ular and tubular compartments in MutuDCs (Figures 4B and 4C;
Video S1). We also pulsed MutuDC with fluorescent dextran
and subsequently treated them with prazosin or tamoxifen. In
control cells, dextran remained contained within endolysosomal
compartments; in prazosin- and tamoxifen-treated cells, we
observed dextran leakage into the cytosol (Figures 4D and 4E).
The accessibility of the endolysosomal lumen to a cytosolic ga-
lectin-3 probe, as well as release of internalized dextran into the
cytosol, demonstrates that in prazosin-treated cells endolysoso-
mal membranes become permeable. In summary, we conclude
that both prazosin and tamoxifen target endocytic compart-
ments, causing membrane destabilization and leakage of con-
tents, including internalized antigens, into the cytosol.
Lysosomotropic Properties of Quinazolinamines
Mediate Import Enhancement
Considering that in dendritic cells, prazosin had a highly spe-
cific effect on lysosome permeability, we hypothesized that
the enhancement of antigen import might be mediated through
lysosomal trapping of the drugs. Lysosomal trapping occurs
when a compound readily crosses membranes at neutral pH,
but becomes protonated and membrane impermeable at acidic
pH (Figure S5A). This phenomenon has been observed for
several classes of amine group-containing, amphiphilic com-
pounds (Nadanaciva et al., 2011). Interestingly, the majority of
the hits have physicochemical properties of lysosomotropic
compounds, i.e., a pKa between 6.5 and 11 and a logP value
>2 (Figure 5A). We used BODIPY-conjugated prazosin to deter-
mine whether prazosin undergoes lysosomal trapping (Figures
S5B and S5C). Indeed, within seconds following addition, pra-
zosin-BODIPY rapidly accumulated in vacuolar compartments
in MutuDCs, positive for fluorescently labeled wheat germ
agglutinin (WGA) (Figure 5B). This localization of the dye was
dependent on the prazosin moiety, as BODIPY alone (that
stains lipid droplets) did not colocalize with WGA (Figure 5B).
As predicted, accumulation of prazosin-BODIPY was depen-
dent on the low pH of the endolysosomal compartments and
was greatly diminished in cells pretreated with NH4Cl (Figures
5C and 5D).Figure 3. Dynamic Organellar Mapping to Identify the Subcellular Cha
MutuDCs were treated with either prazosin, tamoxifen, or DMSO (control) for 4 h i
Statistical comparison of organellar maps made with different treatments was pe
(A) Drug-induced shifts in protein subcellular localization detected using a ‘‘MR’’ p
the movement (R score) between maps was determined. Purple lines indicate cut
shown for comparison (and vice-versa). Most prazosin hits are also tamoxifen hi
(B) Shifting proteins from tamoxifen and prazosin-treated samples represented o
(C)MRplot highlighting all detected lysosomal proteins (soluble, transmembrane,
show distribution of the M scores for transmembrane and soluble lysosomal pro
p values were calculated using the Mann-Whitney U test. See also Figure S3 andTo test whether lysosomal trapping of the compounds is
required for antigen import enhancement, we performed the
b-lactamase import assay in the presence and absence of
NH4Cl to neutralize the lysosomal pH. For all four compounds
tested (prazosin, tamoxifen, DbeQ, and importazole), the
enhancement of b-lactamase import was completely abolished
in the presence of NH4Cl (Figures 5E and S5D). Intriguingly,
neither NH4Cl nor chloroquine alone enhanced antigen import
in MutuDCs, suggesting that dissipation of endolysosomal pH
is not sufficient for import enhancement (Figures S5D–S5F).
NH4Cl also abolished prazosin-mediated release of dextran
into the cytosol (Figures 5F and 5G). Together, these data sup-
port themodel where endolysosomal accumulation of the import
enhancers leads to destabilization of the antigen-containing
compartments.
Antigen Import Enhancers Augment Cross-Presentation
and Cross-Priming
To determine if enhanced antigen import results in increased an-
tigen cross-presentation to CD8+ T cells, we fed DCs with solu-
ble ovalbumin (sOVA) prior to treatment with the drugs and incu-
bation with Kb/OVA257–264-specific B3Z T cell hybridoma. Both
prazosin and tamoxifen treatment led to a dramatic, concentra-
tion-dependent enhancement of B3Z activation (Figure 6A). We
observed a similar enhancement of cross-presentation of cell
associated antigens (Figure 6B); in these experiments we co-
cultured 3T3s (H2-Kd) expressing cytosolic OVA with MutuDCs
for 5 h in the presence or absence of prazosin, and added the
B3Z hybridomas to fixed co-cultures. As demonstrated using a
membrane labeling dye (PKH-26+), prazosin did not increase up-
take of cell-associated material (Figure 6C). Importantly, we
were also able to enhance cross-presentation of endotoxin-
free sOVA (Figure 6D), which is normally not cross-presented
efficiently due to the absence of TLR agonists (Alloatti et al.,
2016; Burgdorf et al., 2008). This enhancement was not due to
prazosin-mediated DC activation, because we did not observe
upregulation of activation markers in prazosin-treated DCs (Fig-
ure 6E). Prazosin also did not lead to changes in localization or
abundance of MHC class I or of the components of the loading
complex (Figures S6A and S6B). Importantly, prazosin did not
enhance T cell activation when DCs were pulsed with the short
OVA257–264 peptide (that binds to MHC I without the need for
intracellular processing), indicating that it does not affect the
general ability of DCs to activate T cells (Figures 6F and S6C).
Finally, in accordance with the proposed mechanism of prazosin
action, we did not observe an increase in cross-presentation
enhancement when prazosin was added in the presence ofnges in Protein Distribution on Drug Treatment
n biological duplicate, and samples were processed as described in Figure 2A.
rformed to identify proteins with profile shifts/altered subcellular localization.
lot analysis. For each protein, themovement (M score) and the reproducibility of
-offs for significance. In the prazosin plot the hits from tamoxifen treatment are
ts or near-hits.
n the organellar map of MutuDCs. Most shared hits are lysosomal proteins.
and peripheral [located on the cytosolic side of themembrane]). The histograms
teins.
Data S2.
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Figure 4. Prazosin and Tamoxifen Lead to Lysosomal Leakage
(A) Analysis of whole cell proteome and cytosol fractions from MutuDCs treated with prazosin, tamoxifen, or DMSO (control) for 4 h. The relative abundance of
proteins from prazosin or tamoxifen versus vehicle-treated cells in whole cell versus cytosol proteomes. The histograms show distributions of all (gray) versus
lysosomal (purple) proteins. TM, transmembrane; SOL, soluble. p values were calculated using the Kolmogorov-Smirnov test. n = 2 for whole cell lysates (SILAC
quantification), n = 4 for cytosol fractions (label-free quantification).
(B and C) MutuDCs stably expressing galectin-3-YFP were treated with 20 mM prazosin and imaged continuously for 40 min.
(B) Examples of control and prazosin-treated galectin-3-YFP-positive cells. Scale bar, 20 mm.
(C) Quantification of galectin-3-YFP recruitment in control and prazosin-treated cells from a representative movie. Each dot represents a sum of galectin-3-YFP
spot areas per cell over the duration of the movie (40 min). Box and whiskers plot visualizes median, first, and third quartiles (hinges) and the smallest/largest
observation no further than 1.5 * IQR (interquartile range) from the respective hinge (whiskers). p values were calculated using Mann-Whitney U test. Data
representative of two experiments.
(D and E) MutuDCs were pulsed with 1 mg/mL 3K dextran-TRITC for 45 min and treated with 20 mM prazosin or tamoxifen for 1 h.
(D) Representative images. Scale bar, 20 mm.
(E) Quantification of the cytosolic fluorescence. Each dot represents a cell (three samples per condition). p valueswere calculated usingMann-Whitney U test with
Bonferroni correction (comparing with the control group). Box and whiskers plot visualizes median, first, and third quartiles (hinges) and the smallest/largest
observation no further than 1.5 * IQR from the respoective hinge (whiskers).
See also Figure S4 and Video S1.







Figure 5. Antigen Import Enhancement Is a Consequence of Lysosomal Trapping
(A) Physicochemical properties (according to DrugBank data) of all the compounds present in the FDA library and of those active in the antigen import assay
(yEC50 <40 mM, see Figure 1F). All but one of the hits has physicochemical properties similar to those of lysosomotropic compounds (see also Figure S5A).
(B) MutuDCs cells were pulsed with 10 mg/mL WGA-Alexa Fluor 633 for 45 min and imaged immediately after addition of 5 mM prazosin-BODIPY or 10 mg/mL
BODIPY. Representative data from one of two independent experiments. Scale bar, 10 mM.
(C and D) MutuDCs were pre-treated with 10 mM NH4Cl and imaged immediately following addition of prazosin-BODIPY.
(C) Representative images, scale bar 10 mM.
(D) Number of prazosin-BODIPY spots per cell (80 cells per condition per experiment, three independent experiments). p value was calculated using Mann-
Whitney U test. Box and whiskers plot visualizes median, first and third quartiles (hinges) and the smallest/largest observation no further than 1.5 * IQR from the
respective hinge (whiskers).
(E) Antigen import assay (Figure 1A) was performed in the presence of prazosin, importazole, tamoxifen, and DbeQ with or without NH4Cl. Representative plots
are shown (prazosin, n = 3; tamoxifen, importazole, and DbeQ, n = 2).
(F and G) MutuDCs were pulsed with 3K dextran-TRITC for 45 min and incubated with 20 mM prazosin, 10 mM NH4Cl, or both for 45 min.
(F) Representative images; scale bar, 20 mM.
(G)Quantificationofcytosolic fluorescence.Eachdot representsonecell; fluorescencewasquantified for 100cells perconditionper experimentwith four independent
experiments (including data in Figure 4E). p valueswere calculated usingMann-WhitneyU testwithBonferroni correction (comparingwith the control group). Box and
whiskers plot visualizes median, first, and third quartiles (hinges) and smallest/largest observation no further than 1.5 * IQR from the respective hinge (whiskers).
See also Figure S5.
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Figure 6. Prazosin Enhances Cross-Presentation and Cross-Priming
(A) Antigen cross-presentation assay with B3Z hybridoma in the presence of increasing concentrations of prazosin or tamoxifen. The cells were pulsedwith sOVA
for 45 min, followed by 3.5 h incubation in the presence of the indicated compounds. Representative of three independent experiments.
(B) The effect of prazosin on cross-presentation of cell-derived antigens. 3T3 cells expressing cytosolic OVA were used as antigen source and co-cultured with
MutuDCs in for 5 h in the presence or absence of prazosin. Mean from three independent experiments ±SE.
(legend continued on next page)






OPEN ACCESSNH4Cl or chloroquine suggesting endolysosomal accumulation
of prazosin is required for the observed phenotype (Figures 6G
and S6C). Considering that inhibiting lysosomal degradation
alone (by NH4Cl, chloroquine, or peptidase inhibitor E64) did
not facilitate cross-presentation in MutuDC (Figure S6C), we
also concluded that it is unlikely that prazosin acts primarily by
protecting antigens from degradation. Together, these data indi-
cate that facilitating antigen import into the cytosol overcomes
the requirement for DC activation during cross-presentation
and suggests that antigen import might be a key regulatory
step that determines which antigens are destined for cross-
presentation.
We went on to determine if endosomal processing of antigens
for presentation onMHC class II was also enhanced by prazosin.
We fed DCs with soluble endotoxin-free OVA, cell-associated
OVA, or the appropriate peptides that bind directly to MHC mol-
ecules and co-cultured them with OT-I (CD8+) and OT-II (CD4+)
T cells (specific for Kb/OVA257–264 and I-A
b/OVA323–339, respec-
tively). As shown in Figure 6H, presentation of soluble and cell-
associated antigens to CD4+ OT-II cells was not affected by pra-
zosin. This was in clear contrast with Poly(I:C), which strongly
enhanced sOVA presentation to CD4+ but not to CD8+ T cells.
Again, prazosin did not enhance T cell priming when DCs were
treated with the short peptides directly, which would not require
import into the cytosol for presentation. In summary, prazosin
enhances antigen cross-presentation selectively and indepen-
dently of DC maturation.
Finally, we investigated whether prazosin could be used to
enhance antigen cross-presentation and anti-tumor immunity
in vivo. In mice bearing MC38-GFP-OVA tumors, we observed
reduced tumor growth following systemic treatment with prazo-
sin (Figure 6I). In the more aggressive tumor model B16-OVA,
prazosin alone was insufficient to control tumor growth and
neither was a checkpoint inhibitor, anti-PD-1. However, combi-
nation of prazosin and anti-PD-1 led to a synergistic effect and
a significant delay in tumor growth (Figure 6J). To rule out that
this growth delay was caused by a direct effect of the treatment(C) Phagocytosis efficiency in the presence and absence of prazosin. 3T3s were l
2 h of co-culture. Mean from three independent experiments ± SE.
(D) MutuDCs were incubated with sOVA or sOVA EF for 45 min followed by 3.5 h
efficiency (representative plot from three independent experiments, error bars in
(E) For the analysis of DC activation, MutuDCs were incubated with sOVA/EF s
incubated for 16 h at 37C, and stained with anti-CD86 (gated for live cells only)
(F) MutuDCs were incubated with the MHC I peptide in the presence or absence
Mean from three independent experiments ±SE.
(G) MutuDCs were incubated with sOVA EF in the presence of indicated compoun
Mean from three independent experiments ±SE.
(H) The effect of prazosin on antigen presentation to OT-I and OT-II cells. MutuD
peptides in the presence or absence of prazosin or Poly(I:C).
(I) Tumor growth. Mice were injected subcutaneously (SC) with the MC38-OVA
temically (intraperitoneally, i.p.) with 0.5 mg prazosin or vehicle control, 33week. M
of mice with tumors smaller than 250 mm3 at the end of the experiment. Lower p
means and SDwere calculated using loess regression, the statistical significance
Benjamini-Hochberg correction. ***p < 0.001 ****p < 0.0001.
(J) Tumor growth curves for mice injected s.c. with the B16-OVA tumor cells. Fro
week with 0.5 mg prazosin, 150 mg anti-PD-1, or the combination of both. Mice p
curves for all groups, where means and SD were calculated using loess regressio
test and FDR Benjamini-Hochberg correction. **p < 0.01, ****p < 0.0001.
See also Figure S6.on the tumor, we implanted B16 tumors in immunodeficient non-
obese diabetic (NOD)/severe combined immunodeficiency
(SCID)/IL-2Rg-null mice (NSG). In the NSG mice, we did not
observe any reduction of tumor volume with PD-1/prazosin
treatment (Figure S6D). We conclude that a combination of
checkpoint blockade and increased antigen cross-presentation
can overcome resistance of certain tumors to immunotherapy.
DISCUSSION
In this study, we developed a strategy to harness the natural ca-
pacity of DCs to cross-present antigens bymodulating a specific
step involved in antigen processing: import into the cytosol. To
enhance antigen import, we used small molecules identified
through a pharmacological screen. We demonstrated that
import is a rate-limiting step for cross-presentation, in particular
for antigens free of pathogen-derived signals. This observation
reinforces the hypothesis that import into the cytosol is a regu-
lated step (Zehner et al., 2015), and implies that endogenous sig-
nals that drive import and cross-presentation in the absence of
infection await identification.
Boosting antigen import and cross-presentation synergizes
with anti-PD-1-mediated immunotherapy in a tumor model unre-
sponsive to the antibody alone, suggesting that cytosolic antigen
cross-presentation plays a critical role in anti-tumor immune re-
sponses. Thus, enhancing antigen cross-presentation with small
molecules provides a strategy for combination therapies with
checkpoint blockers. This approach of enhancing anti-tumor im-
munity still relies on the presence of neoantigens. Yet, it has a
major advantage over tumor antigen-containing vaccines, in
that enhancing the natural capacity of DCs to route internalized
antigens for cross-presentation does not require prior identifica-
tion of specific epitopes.
We report here over 30 FDA-approved small molecule
enhancers of antigen import, and we characterize the effects
of two molecules (prazosin and tamoxifen) in more detail. Using
a combination of proteomics, microscopy, and bioinformatics,abeled with PKH26, and acquisition of the dye by MutuDCs was analyzed after
incubation with prazosin. B3Z assay was used to monitor cross-presentation
dicate SEM from technical duplicates).
OVA in the presence and in the absence of prazosin for 5 h, washed, further
.
of prazosin for 5 h, washed, fixed, and incubated with B3Z hybridoma for 16 h.
ds for 5 h, and antigen cross-presentation was detected with B3Z hybridomas.
C were incubated with sOVA EF, OVA-expressing 3T3s, or MHC class I or II
tumor cell. When tumors became detectable, the animals were treated sys-
ice pooled from two independent experiments. The numbers indicate number
anel represents best-fit curves for control and prazosin-treated groups, where
was calculated using ANOVAwith the Tukey test and false discovery rate (FDR)
m the day when tumors became detectable, mice were treated three times per
ooled from three independent experiments. The last panel represents best-fit
n. The statistical significance was calculated using ANOVA with the Dunnett’s
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quence of lysosomal trapping of the drugs and increased lyso-
somal permeability. Other lysosomotropic compounds, such
as chloroquine and NH4Cl, have been shown to raise endolyso-
somal pH, inhibit lysosomal degradation, and as a result, in-
crease cross-presentation efficiency (Accapezzato et al., 2005;
Belizaire and Unanue, 2009; Chatterjee et al., 2012; Hotta
et al., 2006; Me´nager et al., 2014). Intriguingly, this effect was
observed primarily in macrophages and human monocyte-
derived DCs; in immature mouse bone-marrow-derived DCs,
chloroquine and NH4Cl had either an inhibitory or no effect on
cross-presentation (Datta et al., 2003; Jancic et al., 2007; Kovac-
sovics-Bankowski and Rock, 1995; Oura et al., 2011; Rodriguez
et al., 1999; Sehrawat et al., 2013). Neither NH4Cl nor chloro-
quine increased the efficiency of antigen import or cross-presen-
tation in MutuDCs, and instead, they abolished the effect of
import enhancers. The observation that antigens internalized
by cDC1s may persist for a longer time (Thacker and Janssen,
2012; Reboulet et al., 2010) could explain why inhibiting lyso-
somal degradation has also no effect on cross-presentation in
MutuDCs. Therefore, accumulation in lysosomes is necessary
for the activity of the small molecules we identified in this study,
but lysosomotropism in itself does not promote endolysosomal
permeability.
A number of mechanisms have been proposed by which
lysosomotropic compounds could destabilize membranes.
For instance, sunitinib and mefloquine, present among our
top hits, have the ability to directly fluidize lysosomal mem-
branes (Zhitomirsky et al., 2018). Other enhancers of antigen
import, such as chlorpromazine, perphenazine, or fluphenazine
displace lysosomal lipid hydrolases from the inner leaflet of the
lysosome and destabilize membranes by inducing changes in
their lipid composition (Kornhuber et al., 2010). Although the ly-
sosomotropism of phenothiazines has been extensively stud-
ied, lysosomotropic properties (and corresponding effects) of
quinazolinamine-derived compounds—the most potent chemi-
cal group in the antigen import assay—have not been studied
in detail. Interestingly, the drug library used here also includes
other compounds previously shown to permeabilize lysosomes
that were not active in the b-lactamase assay (e.g., norfloxacin
and ciprofloxacin, which destabilize lysosomes in cancer cells).
Further work will be required to determine what confers spec-
ificity of the compounds, but differences in pH, membrane
composition, and proteolytic content of endolysosomal com-
partments are likely to influence the extent and consequences
of lysosomal trapping for the different classes of lysosomo-
tropic compounds.
Many of the clinically approved drugs demonstrate unex-
pected activities that have either a harmful or a beneficial effect
for the patient (Pushpakom et al., 2019). These hidden effects
can also be exploited for new therapeutic indications in drug re-
positioning approaches. Yet, predicting or identifying effects of
small molecules on target cells remains challenging. Here, we
took advantage of the fact that localization and/or trafficking pat-
terns of proteins are integral to most aspects of cellular func-
tions. We demonstrated that comparative organellar mapping
provides an effective and generic strategy for unbiased identifi-
cation of biological effects of small molecules. This approach12 Cell Reports 32, 107905, July 14, 2020can be used to characterize changes in subcellular localization
of thousands of proteins simultaneously (without the need for an-
tibodies or protein tagging) and to characterize on- and off-target
effects in any cell type of choice (including primary cells). To our
knowledge, this is a first report of organellar mapping in cDC1s
(or dendritic cells altogether), and it provides a useful resource
of information on subcellular localization and abundance of
poorly characterized proteins that are not expressed in common
cell lines (organellar map and full proteome composition are
available at http://dc-biology.mrc-lmb.cam.ac.uk).
In summary, through a combination of small molecule
screening and proteomics-based molecular mapping, we estab-
lished an approach for enhancing presentation of antigens
sampled by DCs in the absence of strong immunogenic signals.
Enhancing cross-presentation with small molecules may in the
future provide therapeutic regimes for patients that do not
respond to currently available treatment options.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d RESOURCE AVAILABILITYB Lead Contact
B Materials Availability
B Data and Code Availability
d EXPERIMENTAL MODELS
B Animals
B Cell lines and cell culture
d METHOD DETAILS
B Compounds and antibodies
B Cell culture
B Antigen import assay and library screen
B Chemical class and target assignment
B Cross-presentation assay
B OTI and OTII activation assays
B Cross-presentation of cell-associated antigens
B Cell uptake assay
B DC activation
B Live microscopy
B Galectin 3-YFP accumulation
B Dextran release assays
B Prazosin-BODIPY accumulation
B MC38-GFP-OVA tumour growth experiments
B B16-OVA tumour growth experiments
B Whole cell proteomics
B Proteomic analysis of cytosol
B Dynamic organellar maps
B Mass spectrometry and data processing
B Bioinformatic analysis of the proteomic data
B Copy number estimates of proteins expressed in Mu-
tuDC
B Drug-induced changes in whole cell proteomes
B Drug-induced changes in cytosol
B Organellar maps
B Subcellular localization predictions in MutuDC
Resource
ll
OPEN ACCESSB Drug induced protein movements
d QUANTIFICATION AND STATISTICAL ANALYSIS
d ADDITIONAL RESOURCES
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
celrep.2020.107905.
ACKNOWLEDGMENTS
Wewould like to thank Hans Acha-Orbea for the MutuDCs, Matthew Albert for
the NIH/3T3 cells expressing a non-secretable form of OVA, Felix Randow for
the galectin-3-YFP construct, Jon Howe for help with microscopy, and Greg
S1odkowicz for help with statistical analysis. D.N.I. and G.H.H.B. also wish
to thank Matthias Mann for his support. S.A. received funding from Institute
Curie; Institut National de la Sante´ et de la Recherche Me´dicale; Centre Na-
tional de la Recherche Scientifique; la Ligue Contre le Cancer (Equipe labelli-
se´e Ligue, EL2014.LNCC/SA); Association de Recherche Contre le Cancer
(ARC); the ERC (2013-AdG 340046 DCBIOX); INCA (PLBIO13-057); ANR-11-
LABX-0043 and ANR-10-IDEX-0001-02 PSL; and ANR-16-CE15001801 and
ANR-16-CE18002003. P.K. was supported by EMBO (ALTF 467-2012), the
Wellcome Trust (101578/Z/13/Z), and Medical Research Council
(U105178805). A.A. was supported by EMBO (ALTF 883-2011). D.N.I. was
funded by the Louis-Jeantet Foundation and the Max Planck Society for the
Advancement of Science. G.H.H.B. was funded by the German Research
Foundation (DFG/Gottfried Wilhelm Leibniz Prize) and the Max Planck Society
for the Advancement of Science.
AUTHOR CONTRIBUTIONS
P.K. performed, analyzed, designed, and supervised most of the experiments.
M.G. performed and analyzed part of the antigen presentation assays and set
up and carried out experiments with cell-associated antigens. D.N.I. carried
out the proteomic experiments and assisted with data analysis. L.J. and
S.H.-C. performed tumor experiments and assisted with animal work. P.A.K.
assisted with the B3Z assays. P.R.-S. assisted with the dextran release as-
says. M.G. and A.A. assisted with tumor experiments. J.G.M. assisted in assay
development and experimental design. E.D.N. assisted with design of the
small molecule screening assays. G.H.H.B. designed the proteomics experi-
ments, performed the data analysis, and supervised the proteomics work.
P.K. and S.A. conceived and supervised the study. P.K., G.H.H.B., and S.A.
wrote the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: September 16, 2019
Revised: May 15, 2020
Accepted: June 24, 2020
Published: July 14, 2020
REFERENCES
Accapezzato, D., Visco, V., Francavilla, V., Molette, C., Donato, T., Paroli, M.,
Mondelli, M.U., Doria, M., Torrisi, M.R., and Barnaba, V. (2005). Chloroquine
enhances human CD8+ T cell responses against soluble antigens in vivo.
J. Exp. Med. 202, 817–828.
Ackerman, A.L., Kyritsis, C., Tampe´, R., and Cresswell, P. (2003). Early phag-
osomes in dendritic cells form a cellular compartment sufficient for cross pre-
sentation of exogenous antigens. Proc. Natl. Acad. Sci. USA 100, 12889–
12894.
Alloatti, A., Kotsias, F., Magalhaes, J.G., and Amigorena, S. (2016). Dendritic
cell maturation and cross-presentation: timing matters!. Immunol. Rev. 272,
97–108.Alloatti, A., Rookhuizen, D.C., Joannas, L., Carpier, J.-M., Iborra, S., Magal-
haes, J.G., Yatim, N., Kozik, P., Sancho, D., Albert, M.L., and Amigorena, S.
(2017). Critical role for Sec22b-dependent antigen cross-presentation in anti-
tumor immunity. J. Exp. Med. 214, 2231–2241.
Belizaire, R., andUnanue, E.R. (2009). Targeting proteins to distinct subcellular
compartments reveals unique requirements for MHC class I and II presenta-
tion. Proc. Natl. Acad. Sci. USA 106, 17463–17468.
Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M.C., and
Steinman, R.M. (2002). Efficient targeting of protein antigen to the dendritic
cell receptor DEC-205 in the steady state leads to antigen presentation onma-
jor histocompatibility complex class I products and peripheral CD8+ T cell
tolerance. J. Exp. Med. 196, 1627–1638.
Borner, G.H.H. (2020). Organellar maps through proteomic profiling - a con-
ceptual guide. Mol. Cell. Proteomics 19, 1076–1087.
Bo¨ttcher, J.P., and Reis e Sousa, C. (2018). The Role of Type 1 Conventional
Dendritic Cells in Cancer Immunity. Trends Cancer 4, 784–792.
Brunner, C., Seiderer, J., Schlamp, A., Bidlingmaier, M., Eigler, A., Haimerl, W.,
Lehr, H.A., Krieg, A.M., Hartmann, G., and Endres, S. (2000). Enhanced den-
dritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA
drives T cell activation in vitro and therapeutic anti-tumor immune responses
in vivo. J. Immunol. 165, 6278–6286.
Burgdorf, S., Scho¨lz, C., Kautz, A., Tampe´, R., and Kurts, C. (2008). Spatial and
mechanistic separation of cross-presentation and endogenous antigen pre-
sentation. Nat. Immunol. 9, 558–566.
Caminschi, I., Proietto, A.I., Ahmet, F., Kitsoulis, S., Shin Teh, J., Lo, J.C.Y.,
Rizzitelli, A., Wu, L., Vremec, D., van Dommelen, S.L.H., et al. (2008). The den-
dritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine
enhancement. Blood 112, 3264–3273.
Cebrian, I., Visentin, G., Blanchard, N., Jouve, M., Bobard, A., Moita, C., En-
ninga, J., Moita, L.F., Amigorena, S., and Savina, A. (2011). Sec22b regulates
phagosomal maturation and antigen crosspresentation by dendritic cells. Cell
147, 1355–1368.
Chatterjee, B., Smed-So¨rensen, A., Cohn, L., Chalouni, C., Vandlen, R., Lee,
B.-C., Widger, J., Keler, T., Delamarre, L., and Mellman, I. (2012). Internaliza-
tion and endosomal degradation of receptor-bound antigens regulate the effi-
ciency of cross presentation by human dendritic cells. Blood 120, 2011–2020.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide pro-
tein quantification. Nat. Biotechnol. 26, 1367–1372.
Crittenden, M.R., Zebertavage, L., Kramer, G., Bambina, S., Friedman, D.,
Troesch, V., Blair, T., Baird, J.R., Alice, A., and Gough, M.J. (2018). Tumor
cure by radiation therapy and checkpoint inhibitors depends on pre-existing
immunity. Sci. Rep. 8, 7012.
Datta, S.K., Redecke, V., Prilliman, K.R., Takabayashi, K., Corr, M., Tallant, T.,
DiDonato, J., Dziarski, R., Akira, S., Schoenberger, S.P., and Raz, E. (2003). A
subset of Toll-like receptor ligands induces cross-presentation by bone
marrow-derived dendritic cells. J. Immunol. 170, 4102–4110.
Falo, L.D., Jr., Kovacsovics-Bankowski, M., Thompson, K., and Rock, K.L.
(1995). Targeting antigen into the phagocytic pathway in vivo induces protec-
tive tumour immunity. Nat. Med. 1, 649–653.
Fuertes Marraco, S.A., Grosjean, F., Duval, A., Rosa, M., Lavanchy, C., Ashok,
D., Haller, S., Otten, L.A., Steiner, Q.-G., Descombes, P., et al. (2012). Novel
murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research.
Front. Immunol. 3, 331.
Gilfillan, S., Chan, C.J., Cella, M., Haynes, N.M., Rapaport, A.S., Boles, K.S.,
Andrews, D.M., Smyth, M.J., and Colonna, M. (2008). DNAM-1 promotes acti-
vation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells
and tumors. J. Exp. Med. 205, 2965–2973.
Giodini, A., and Cresswell, P. (2008). Hsp90-mediated cytosolic refolding of
exogenous proteins internalized by dendritic cells. EMBO J. 27, 201–211.
Gros, M., and Amigorena, S. (2019). Regulation of Antigen Export to the
Cytosol During Cross-Presentation. Front. Immunol. 10, 41.Cell Reports 32, 107905, July 14, 2020 13
Resource
ll
OPEN ACCESSGrotzke, J.E., Kozik, P., Morel, J.-D., Impens, F., Pietrosemoli, N., Cresswell,
P., Amigorena, S., and Demangel, C. (2017). Sec61 blockade by mycolactone
inhibits antigen cross-presentation independently of endosome-to-cytosol
export. Proc. Natl. Acad. Sci. USA 114, E5910–E5919.
Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., Van Endert, P., and
Amigorena, S. (2003). ER-phagosome fusion defines an MHC class I cross-
presentation compartment in dendritic cells. Nature 425, 397–402.
Hammerich, L., Marron, T.U., Upadhyay, R., Svensson-Arvelund, J., Dhainaut,
M., Hussein, S., Zhan, Y., Ostrowski, D., Yellin, M.,Marsh, H., et al. (2019). Sys-
temic clinical tumor regressions and potentiation of PD1 blockade with in situ
vaccination. Nat. Med. 25, 814–824.
Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Ko-
hyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., et al.
(2008). Batf3 deficiency reveals a critical role for CD8a+ dendritic cells in cyto-
toxic T cell immunity. Science 322, 1097–1100.
Hotta, C., Fujimaki, H., Yoshinari, M., Nakazawa, M., and Minami, M. (2006).
The delivery of an antigen from the endocytic compartment into the cytosol
for cross-presentation is restricted to early immature dendritic cells. Immu-
nology 117, 97–107.
Imai, J., Hasegawa, H., Maruya, M., Koyasu, S., and Yahara, I. (2005). Exoge-
nous antigens are processed through the endoplasmic reticulum-associated
degradation (ERAD) in cross-presentation by dendritic cells. Int. Immunol.
17, 45–53.
Itzhak, D.N., Tyanova, S., Cox, J., and Borner, G.H. (2016). Global, quantitative
and dynamic mapping of protein subcellular localization. eLife 5, e16950.
Itzhak, D.N., Davies, C., Tyanova, S., Mishra, A., Williamson, J., Antrobus, R.,
Cox, J., Weekes, M.P., and Borner, G.H.H. (2017). A Mass Spectrometry-
Based Approach for Mapping Protein Subcellular Localization Reveals the
Spatial Proteome of Mouse Primary Neurons. Cell Rep. 20, 2706–2718.
Itzhak, D.N., Schessner, J.P., and Borner, G.H.H. (2019). Dynamic Organellar
Maps for Spatial Proteomics. Curr. Protoc. Cell Biol. 83, e81–e29.
Jancic, C., Savina, A., Wasmeier, C., Tolmachova, T., El-Benna, J., Dang,
P.M.-C., Pascolo, S., Gougerot-Pocidalo, M.-A., Raposo, G., Seabra, M.C.,
and Amigorena, S. (2007). Rab27a regulates phagosomal pH and NADPH ox-
idase recruitment to dendritic cell phagosomes. Nat. Cell Biol. 9, 367–378.
Kornhuber, J., Tripal, P., Reichel, M., M€uhle, C., Rhein, C., Muehlbacher, M.,
Groemer, T.W., and Gulbins, E. (2010). Functional Inhibitors of Acid Sphingo-
myelinase (FIASMAs): a novel pharmacological group of drugs with broad clin-
ical applications. Cell. Physiol. Biochem. 26, 9–20.
Kovacsovics-Bankowski, M., and Rock, K.L. (1995). A phagosome-to-cytosol
pathway for exogenous antigens presented on MHC class I molecules. Sci-
ence 267, 243–246.
Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N., and Mann, M. (2014). Minimal,
encapsulated proteomic-sample processing applied to copy-number estima-
tion in eukaryotic cells. Nat. Methods 11, 319–324.
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y., Maciejewski,
A., Arndt, D., Wilson, M., Neveu, V., et al. (2014). DrugBank 4.0: shedding new
light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097.
Lundberg, E., and Borner, G.H.H. (2019). Spatial proteomics: a powerful dis-
covery tool for cell biology. Nat. Rev. Mol. Cell Biol. 20, 285–302.
MacDonald, M.L., Lamerdin, J., Owens, S., Keon, B.H., Bilter, G.K., Shang, Z.,
Huang, Z., Yu, H., Dias, J., Minami, T., et al. (2006). Identifying off-target effects
and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2, 329–337.
Me´nager, J., Ebstein, F., Oger, R., Hulin, P., Nedellec, S., Duverger, E., Leh-
mann, A., Kloetzel, P.-M., Jotereau, F., and Guilloux, Y. (2014). Cross-presen-
tation of synthetic long peptides by human dendritic cells: a process depen-
dent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PLoS
ONE 9, e89897.
Nadanaciva, S., Lu, S., Gebhard, D.F., Jessen, B.A., Pennie, W.D., and Will, Y.
(2011). A high content screening assay for identifying lysosomotropic com-
pounds. Toxicol. In Vitro 25, 715–723.14 Cell Reports 32, 107905, July 14, 2020Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W.,
Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017). An immunogenic per-
sonal neoantigen vaccine for patients with melanoma. Nature 547, 217–221.
Oura, J., Tamura, Y., Kamiguchi, K., Kutomi, G., Sahara, H., Torigoe, T., Himi,
T., and Sato, N. (2011). Extracellular heat shock protein 90 plays a role in trans-
locating chaperoned antigen from endosome to proteasome for generating
antigenic peptide to be cross-presented by dendritic cells. Int. Immunol. 23,
223–237.
Palmowski, M.J., Gileadi, U., Salio, M., Gallimore, A., Millrain, M., James, E.,
Addey, C., Scott, D., Dyson, J., Simpson, E., and Cerundolo, V. (2006). Role
of immunoproteasomes in cross-presentation. J. Immunol. 177, 983–990.
Pushpakom, S., Iorio, F., Eyers, P.A., Escott, K.J., Hopper, S., Wells, A., Doig,
A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019). Drug repurposing:
progress, challenges and recommendations. Nat. Rev. Drug Discov. 18,
41–58.
Reboulet, R.A., Hennies, C.M., Garcia, Z., Nierkens, S., and Janssen, E.M.
(2010). Prolonged antigen storage endows merocytic dendritic cells with
enhanced capacity to prime anti-tumor responses in tumor-bearing mice.
J. Immunol. 185, 3337–3347.
Rock, K.L., and Shen, L. (2005). Cross-presentation: underlying mechanisms
and role in immune surveillance. Immunol. Rev. 207, 166–183.
Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P., and Ami-
gorena, S. (1999). Selective transport of internalized antigens to the cytosol
for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1, 362–368.
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S.,
Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al.
(2016). Expansion and Activation of CD103(+) Dendritic Cell Progenitors at
the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and
BRAF Inhibition. Immunity 44, 924–938.
Sa´nchez-Paulete, A.R., Cueto, F.J., Martı´nez-Lo´pez, M., Labiano, S., Morales-
Kastresana, A., Rodrı´guez-Ruiz, M.E., Jure-Kunkel, M., Azpilikueta, A., Aznar,
M.A., Quetglas, J.I., et al. (2016). Cancer Immunotherapy with Immunomodu-
latory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-
Dependent Dendritic Cells. Cancer Discov. 6, 71–79.
Sa´nchez-Paulete, A.R., Teijeira, A´., Quetglas, J.I., Rodrı´guez-Ruiz, M.E., Sa´n-
chez-Arra´ez, A´., Labiano, S., Etxeberria, I., Azpilikueta, A., Bolan˜os, E., Balles-
teros-Briones, M.C., et al. (2018). Intratumoral Immunotherapy with XCL1 and
sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters
Dendritic Cell-Mediated T-cell Cross-Priming. Cancer Res. 78, 6643–6654.
Sancho, D., Mour~ao-Sa´, D., Joffre, O.P., Schulz, O., Rogers, N.C., Pennington,
D.J., Carlyle, J.R., and Reis e Sousa, C. (2008). Tumor therapy in mice via an-
tigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118,
2098–2110.
Sanderson, S., and Shastri, N. (1994). LacZ inducible, antigen/MHC-specific
T cell hybrids. Int. Immunol. 6, 369–376.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch,
T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an
open-source platform for biological-image analysis. Nat. Methods 9, 676–682.
Sehrawat, S., Koenig, P.-A., Kirak, O., Schlieker, C., Fankhauser, M., and
Ploegh, H.L. (2013). A catalytically inactive mutant of the deubiquitylase
YOD-1 enhances antigen cross-presentation. Blood 121, 1145–1156.
Shen, L., Sigal, L.J., Boes, M., and Rock, K.L. (2004). Important role of
cathepsin S in generating peptides for TAP-independent MHC class I cross-
presentation in vivo. Immunity 21, 155–165.
Thacker, R.I., and Janssen, E.M. (2012). Cross-presentation of cell-associated
antigens by mouse splenic dendritic cell populations. Front. Immunol. 3, 41.
Theisen, D.J., Davidson, J.T., 4th, Brisen˜o, C.G., Gargaro, M., Lauron, E.J.,
Wang, Q., Desai, P., Durai, V., Bagadia, P., Brickner, J.R., et al. (2018).
WDFY4 is required for cross-presentation in response to viral and tumor anti-
gens. Science 362, 694–699.
Thurston, T.L.M., Wandel, M.P., von Muhlinen, N., Foeglein, A., and Randow,
F. (2012). Galectin 8 targets damaged vesicles for autophagy to defend cells
against bacterial invasion. Nature 482, 414–418.
Resource
ll
OPEN ACCESSTyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M.Y., Geiger, T., Mann,
M., and Cox, J. (2016). The Perseus computational platform for comprehen-
sive analysis of (prote)omics data. Nat. Methods 13, 731–740.
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., Franc¸ois, R.,
Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019). Welcome to
the Tidyverse. J. Open Source Softw. 4, 1686.
Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal
sample preparation method for proteome analysis. Nat. Methods 6, 359–362.
Wisniewski, J.R., Hein, M.Y., Cox, J., andMann,M. (2014). A ‘‘proteomic ruler’’
for protein copy number and concentration estimation without spike-in stan-
dards. Mol. Cell. Proteomics 13, 3497–3506.
Yoshida, H., Lareau, C.A., Ramirez, R.N., Rose, S.A., Maier, B., Wroblewska,
A., Desland, F., Chudnovskiy, A., Mortha, A., Dominguez, C., et al.; Immuno-logical Genome Project (2019). The cis-Regulatory Atlas of theMouse Immune
System. Cell 176, 897–912.
Zehner, M., Marschall, A.L., Bos, E., Schloetel, J.-G., Kreer, C., Fehrenschild,
D., Limmer, A., Ossendorp, F., Lang, T., Koster, A.J., et al. (2015). The trans-
locon protein Sec61 mediates antigen transport from endosomes in the
cytosol for cross-presentation to CD8(+) T cells. Immunity 42, 850–863.
Zhitomirsky, B., Yunaev, A., Kreiserman, R., Kaplan, A., Stark, M., and Assaraf,
Y.G. (2018). Lysosomotropic drugs activate TFEB via lysosomal membrane
fluidization and consequent inhibition of mTORC1 activity. Cell Death Dis. 9,
1191.
Zlokarnik, G., Negulescu, P.A., Knapp, T.E., Mere, L., Burres, N., Feng, L.,
Whitney, M., Roemer, K., and Tsien, R.Y. (1998). Quantitation of transcription
and clonal selection of single living cells with beta-lactamase as reporter. Sci-
ence 279, 84–88.Cell Reports 32, 107905, July 14, 2020 15
Resource
ll
OPEN ACCESSSTAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti-CD11c-FITC (clone HL3) BD PharMingen Cat#553801; RRID:AB_395060
anti-CD19-eFluor450 (clone 1D3) eBioscience Cat#48-0193-82; RRID:AB_2734905
anti-CD25-FITC (clone 7D4) BD PharMingen Cat#553072; RRID:AB_394604
anti-CD25-PerCPCy5.5 (clone PC61) BD PharMingen Cat#551071; RRID:AB_394031
anti-CD3-eFluor450 (clone 17A2) eBioscience Cat#48-0032-80; RRID:AB_1272229
anti-CD4-APC (clone RM4-5) BD PharMingen Cat#553051; RRID:AB_398528
anti-CD4-PE-Cy7 (clone RM4-5) BD PharMingen Cat#552775; RRID:AB_394461
anti-CD69-eFluor450 (clone H1.2F3) eBioscience Cat#48-0691-82; RRID:AB_10719430
anti-CD69-PE (clone H1.2F3) BD PharMingen Cat#553237; RRID:AB_394726
anti-CD86-PE (clone GL1) BD PharMingen Cat#553692; RRID:AB_394994
anti-CD8a-PerCP-Cy5.5 (clone 53-6.7) eBioscience Cat#45-0081-82; RRID:AB_1107004
anti-CD8a-Pacific Blue (clone 53-6.7) BD PharMingen Cat#558106; RRID:AB_397029
anti-CD8a-PeCy7 (clone 53-6.7) BD PharMingen Cat#552877; RRID:AB_394506
anti-MHC I (H-2Kb)-FITC (clone AF6-88.5.5.3) eBioscience Cat#11-5958-80; RRID:AB_11151335
anti-MHC II eFluor450 (clone AF120.1, eBioscience) eBioscience Cat#48-5320-80; RRID:AB_10671538
anti-vb 5.1 5.2 TCR-PE (clone MR9-4) BD PharMingen Cat#553190; RRID:AB_394698
anti-Va2 TCR-eFluor450 (clone B20.1) eBioscience Cat#48-5812-82; RRID:AB_10804752
anti-Va2 TCR-PeCy7 (clone B20.1) BD PharMingen Cat#560624; RRID:AB_1727584





Dextran, 3000 MW Tetramethylrhodamine-labeled ThermoFisher Cat#D3307
E64 Sigma-Aldrich Cat#E3132
Eeyarestatin I Sigma-Aldrich Cat#E1286
Importazole Sigma-Aldrich Cat#SML0341
NMS-873 Selleckcheck Cat#S7285
Ovalbumin (endotoxin-free) Hyglos Cat#300036
Ovalbumin (endotoxin-free) Invivogen Cat#vac-pova
Ovalbumin (grade VII) Sigma Aldrich Cat#A7641
PR-619 Sigma-Aldrich Cat#SML0430
Prazosin (in vitro experiments) Sigma-Aldrich Cat#P7791
Prazosin (in vivo experiments) Sigma-Aldrich Cat#1554705
Prazosin-BODIPY ThermoFisher Cat#B7433





Fixable Viability Dye eFluor 780 eBioscience Cat#65-0865-14
LiveBLAzer FRET-B/G Loading Kit ThermoFisher Cat#K1095
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Deposited Data
Proteomics data: whole cell proteomics of MutuDCs,
organellar mapping of MutuDCs
This paper http://dc-biology.mrc-lmb.cam.ac.uk
Experimental Models: Cell Lines
B16-OVA Falo et al., 1995 RRID:CVCL_WM78
B3Z Sanderson and Shastri, 1994 RRID:CVCL_6277
MC38-OVA Gilfillan et al., 2008 N/A
MutuDC Fuertes Marraco et al., 2012 N/A
Experimental Models: Organisms/Strains
Mouse: C57BL/6J (wild type) Charles River Cat#632
Mouse: C57BL/6-Rag1tm1MomTg(TcraTcrb)1100Mjb Taconic Cat#4175
Mouse: C57BL/6-Tg(TcraTcrb)1100Mjb/Crl (OT-1) Charles River Cat#642
Mouse: C57BL/6-Tg(TcraTcrb)425Cbn/Crl (OT-2) Charles River Cat#643
Mouse: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSGTM) Jackson Laboratory Cat#005557
Software and Algorithms
ImageJ/FIJI Schindelin et al., 2012 https://imagej.nih.gov/ij/
GraphPad Prism version 8.4.2 GraphPad Software, La Jolla
California USA
https://www.graphpad.com
MaxQuant version 1.6 Cox and Mann, 2008 https://www.maxquant.org/
Perseus version 1.6 Tyanova et al., 2016 https://www.maxquant.org/
R version 3.5.3 The R Foundation https://www.R-project.org/





Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Patrycja
Kozik (pkozik@mrc-lmb.cam.ac.uk).
Materials Availability
This study did not generate unique reagents.
Data and Code Availability




C57BL/6J wild-type mice, OT-I, Rag1-deficient OT-I, and OT-II transgenic mice were obtained from Charles River Laboratories,
Janvier and Centre de Distribution, Typage et Archive Animal (CDTA, Orleans, France). NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD
scid gamma, NSGTM) mice were originally purchased from the Jackson Laboratory and bred in our animal facility under specific path-
ogen-free conditions. Mice were used between 8-12 weeks old and were gender matched within each experiment (both genders
were used).
All animal procedures were in accordance with the guidelines and regulations of the Institut Curie Veterinary Department and all
mice used were less than six months old.
Cell lines and cell culture
The following cell lines were used in this study: GFP+ MutuDC, obtained from Hans-Acha Orbea (Fuertes Marraco et al., 2012), NIH/
3T3 expressing a non-secretable form of OVA obtained from Matthew Albert, B3Z hybridoma cells (Sanderson and Shastri, 1994),
B16-OVA cells (Falo et al., 1995), MC38-OVA (Gilfillan et al., 2008).





For flow cytometry, the following antibodies were used: anti-CD86-PE (clone GL1, BD PharMingen Cat#553692), anti-CD69-PE
(clone H1.2F3, BD PharMingen Cat#553237), anti-CD25-PerCPCy5.5 (clone PC61, BD PharMingen Cat#551071), anti-CD4-APC
(clone RM4-5, BD PharMingen Cat#553051), anti-CD8a-Pacific Blue (clone 53-6.7, BD PharMingen Cat#558106), anti-Va2-
PeCy7 (clone B20.1, BD PharMingen Cat#560624), anti-CD8a-PeCy7 (clone 53-6.7, BD PharMingen Cat#552877), anti-Va2-
eFluor450 (clone B20.1, eBiosciences Cat#48-5812-82), anti-CD69-eFluor450 (clone H1.2F3, eBiosciences Cat#48-0691-82),
anti-CD25-FITC (clone 7D4, BD PharMingen Cat#553072), anti-CD8a-PerCP-Cy5.5 (clone 53-6.7, eBioscience, Cat#45-0081-82),
anti-TCR vb 5.1-PE (clone MR9-4, BD PharMingen Cat#553190), anti-CD4-PE-Cy7 (clone RM4-5, BD PharMingen Cat#552775),
anti-CD19-eFluor450 (clone 1D3, eBioscience, Cat#48-0193), anti-CD3-eFluor450 (clone 17A2, eBioscience, Cat#48-0032-
80), anti-CD11c-FITC (clone HL3, BD PharMingen Cat#553801), anti-MHC I (H-2Kb)-FITC (clone AF6-88.5.5.3, eBioscience
Cat#11-5958-80), anti-MHC II-eFluor450 (clone AF120.1, eBioscience Cat#48-5320-80).
The following small molecules were used (at the indicated concentrations, unless otherwise stated in the text): DbeQ (4 mM,
Cat#SML0031), importazole (30 mM, Cat#SML0341), PR-619 (20 mM, Cat#SML0430), Eeyarestatin I (10 mM, Cat#E1286), prazosin
(10 mM, Cat#P7791), prazosin (in vivo experiments, Cat#1554705) tamoxifen (10 mM, Cat#T9262), chloroquine (50 mM,
Cat#C6628), E64 (2 mM Cat#E3132, all purchased from Sigma-Aldrich; Prazosin-BODIPY (5 mM, ThermoFisher Scientific,
Cat#B7433), NMS-873 (10 mM, Selleckcheck, Cat#S7285), BODIPY (10 mg/ml, ThermoFisher Scientific, D-3922), SCREEN-
WELL FDA approved drug library V2 (Enzo, Cat#BML-2843-0100), CCF2-FA (ThermoFisher, Cat#K1034).
Cell culture
MutuDCwere grown in IMDM, supplemented with 8% heat-inactivated FCS (Biowest-Biosera), 10 mMHEPES, 2mMGlutamax, 100
IU/ml penicillin, 100 mg/ml streptomycin and 50 mM b-mercaptoethanol (all from Life Technologies).
For SILACmetabolic labeling, MutuDCswere grown in IMDMSILAC culturemedium (Thermo, Cat#88423), supplemented with 8%
(V/V) dialysed fetal calf serum (PAA, Cat#A11-107), 50 mM b-mercaptoethanol (GIBCO), Pencilin and Streptomycin (Sigma), 10 mM
HEPES (pH 7.4), and either: 42 mg/L 13C6,15N4-L-Arginine HCl (Silantes, Cat#201604302) and 73 mg/L 13C6,15N2-L-Lysine HCl
(Silantes, Cat#211604302) for SILAC heavy culture medium; or 42 mg/L L-Arginine HCl and 73 mg/L L-Lysine HCl with standard iso-
topic constituents (Sigma, Cat#A6969 and Cat#L8662) for SILAC light culture medium. Cells were allowed at least seven doublings
prior to experiments, to ensure complete labeling.
NIH/3T3 expressing a non-secretable form of OVA were cultured in DMEM (Life Technologies) supplemented with 10% heat-in-
activated FBS (Biowest-Biosera), 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 10 mM HEPES and 50 mM b-mercap-
toethanol. Necroptosis was induced by treatment with a specific drug ligand (AP20187, BB homodimerizer, Clontech).
B3Z hybridoma cells were cultured in RPMI (Life Technologies), supplemented with 10% FBS (Biowest-Biosera), 0.1 mM non-
essential amino acids, 1 mM sodium pyruvate, 10 mM HEPES and 50 mM b-mercaptoethanol, 10 mM HEPES.
B16-OVA cells were cultured in RPMI, supplemented with 10% heat-inactivated FCS (Biowest-Biosera), 2 mM Glutamax,
100 IU/ml penicillin and 100 mg/ml streptomycin (all from Life Technologies) and selected with G418 2 mg/ml (Life Technnologies)
and hygromycin B 60 mg/ml (GIBCO).
MC38-OVA cells were grown in DMEM, supplemented with 10% heat-inactivated FCS (Biowest-Biosera), 2 mMGlutamax, 100 IU/
ml penicillin and 100 mg/ml streptomycin (all from Life Technologies).
OT-I and OT-II T cells were isolated using EasySep Mouse Naive CD8+ and CD4+ T Cell Isolation Kits respectively (Stemcell,
Cat#19858 and Cat#19765) and cultured in the same media as the B3Z cells.
Antigen import assay and library screen
MutuDCs were seeded at 150,000 cells/well in U-bottom 96-well plates and incubated with 10 mg/ml b-lactamase (Sigma-Aldrich,
Cat#P0389) for 3 h at 37C. The cells were then washed and incubated with small molecules at indicated concentrations for 2 h at
37C. CCF4 loading was performed using LiveBLAzer FRET-B/G Loading Kit (ThermoFisher, Cat#K1095) as described (Cebrian
et al., 2011) for 45-60 min at RT. To increase the sensitivity of the assay, the plates were then incubated for 16 h at RT (Zlokarnik
et al., 1998) in CO2 independent media supplemented with 8% FCS, and 2 mM Glutamax (in the presence of compounds). Immedi-
ately before the flow cytometry analysis, the cells were stained with Fixable Viability Dye eFluor 780 (eBioscience) diluted 1:2500 in
PBS. Proportion of the live cells with a high ratio of blue to green (V450/V530) fluorescence was used as ameasure of the efficiency of
antigen import into the cytosol.
Primary screen of the FDA library. Enzo FDA-approved drug library was screened in the course of three independent experiments.
Each 96-well plate contained threemedia-only, DMSOonly, 4 mMDbeQ (enhancement control), and 10 mMPR-619 (inhibition control)
wells to control for data reproducibility between the plates. The screen was performed once and 37 top ranked compounds were
selected for validation.
Validation screen. The secondary screen was performed at six concentrations (1.25 – 40 mM) for each compound, in two biological
repeats. Media-only and vehicle (DMSO) controls were included on each plate. Wells with less than 500 cells were excluded from
analysis. The raw phenotype measurements (percent of cells with a high ratio of blue-to-green fluorescence) were normalized bye3 Cell Reports 32, 107905, July 14, 2020
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drFitSpline function from the grofit R package. (log2(x+1) transformed values were used for spline fitting). Note that for some drugs
the max effect might not have been reached at the maximum concentration tested, which might result in underestimation of the EC50
values).
Chemical class and target assignment
The information about chemical classes and candidate targets was downloaded from DrugBank database (Law et al., 2014). The
enrichment of chemical classes and targets in active versus non-active compound groups was calculated using Fisher’s test (R stu-
dio). Only the primary target was selected for each drug for the enrichment analysis.
Cross-presentation assay
1x105 MutuDC were seeded in round bottom 96-well plates and incubated with different concentrations of soluble grade VII OVA
(Sigma Aldrich Cat#A7641) or endotoxin-free OVA (Hyglos Cat#300036, Invivogen Cat#vac-pova). Minimal peptide OVA257-264
was used as a control for the capacity of DCs to activate T cells. As indicated, MutuDCs were either incubated with OVA for
45 min, followed by a 3.5 h incubation with small molecules or incubated with OVA and small molecules continuously for 5 h.
Next, DCswerewashed three timeswith 0.1% (vol/vol) PBS/BSA, fixedwith 0.008% (vol/vol) glutaraldehyde for 3min at 4C,washed
twice with 0.2 M glycine and twice with the T cell growth media. 1x105 B3Z hybridoma cells were added per well. After 16 h, the cells
were lysed in a buffer containing 9 mM MgCl2, 0.125% NP40 (Nonidet P40 substitute, Santa Cruz Cat#sc-29102) 1.7 mM chloro-
phenol red-b-D-galactopyranoside (CPRG, Roche Cat#10884308001). CPRG conversion by b-galactosidase was measured by op-
tical density at 590 nm.
OTI and OTII activation assays
1x104 DCs per well were seeded in round bottom 96-well plates and incubated for 5 h with different concentrations of grade VII OVA
(Sigma Aldrich Cat#A7641), endotoxin-free OVA (Hyglos Cat#300036), or control minimal peptides (OVA257-264 and OVA323-339).
Where indicated, prazosin was added at 10 mM or Poly(I:C) at 5 mg/ml. After 5 h, DCs were washed three times with PBS containing
0.1% (vol/vol) BSA and co-culturedwith 1x105 purifiedOT-I CD8+ or OT-II CD4+ T cells for 16h. Formonitoring T cell activation, T cells
were stained for CD69 and CD25 and analyzed by flow cytometry.
Cross-presentation of cell-associated antigens
1x105 (B3Z assay) or 1x104 (OT-I/II assays) MutuDC were seeded in round bottom 96-well plates with 3T3-OVA cells at various 3T3-
OVA:MutuDC ratios (1:2, 1:4, 1:8, 1:16, 1:32). The co-cultures were incubated at 37C in the presence of prazosin (10 mM) or DMSO
(1:1000). After 5 h, the co-cultures were washed, fixed and co-incubated with 1x105 B3Z hybridoma cells or washed and co-cultured
for 16 h with 1x105 purified OT-I or OT-II T cells. B3Z and OTI/II T cell activation was monitored as described above.
Cell uptake assay
NIH/3T3 were stained with the PKH-26 membrane dye (Sigma Aldrich, Cat#PKH26-GL) following the manufacturer’s instructions.
1x105 MutuDC were plated in 96 round bottom-well plates together with PKH-26+ 3T3s at different 3T3:MutuDC ratios (1:2, 1:4,
1:8, 1:16, 1:32). The co-cultures were incubated in the presence of prazosin (10 mM) or DMSO for 2 h or 5 h at 37C, 5% CO2, or
left on ice for 5 h. Cells were then stained with anti-CD11c-APC (clone HL3, BD PharMingen Cat#550261) and violet live/dead
Dye (ThermoFisher Cat#L34955) and fixed to prevent further uptake.
Percentage of PKH-26+MutuDCs (CD11c+ cells) was determined. Phagocytic index was calculated by subtracting the percentage
of PKH-26+ cells in CD11c+ gate obtained at 4C from the percentage of this subset measured at 37C after 2 h or 5 h of incubation.
DC activation
To assess DC activation, 1x105 MutuDC were seeded in round bottom 96-well plates and incubated for 5h with endotoxin-free OVA
(Hyglos Cat#300036) or grade VII OVA (Sigma Aldrich Cat#A7641), in presence or absence of DMSO or prazosin (10 mM). After 5 h,
cells were washed twice with medium, cultured for additional 16 h, and finally stained for CD86.
Live microscopy
MutuDCswere seeded in m-slide 8 well dishes (Ibidi, Cat#80826) and allowed to adhere overnight. All imaging was performed at 37C
with 5%CO2. Images were acquired on a VisiTech iSIM swept field confocal super resolution system coupled to a Nikon Ti2 inverted
microscope stand equippedwith a 100x/1.49 NASRApo TIRF objective lens. Fluorophores were excited simultaneously with 488 nm
and either 561 nm or 640 nm laser light and imaged with two Hamamatsu ORCA-Flash4.0 V3 CMOS cameras via an image splitter
(filter: ZT561rdc from Chroma Technology). The images were analyzed in Fiji (Schindelin et al., 2012) and the panels were assembled
in Adobe Photoshop.Cell Reports 32, 107905, July 14, 2020 e4
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MutuDCs stably expressing galectin-3-YFP were imaged for 40 min immediately after addition of 20 mM prazosin. For quantification
of galectin-3-YFP recruitment, the videosweremanually segmented and spots were identified using the ‘‘Analyse particles’’ function.
For each cell, sum of spot areas in all frames was used as a measure of galectin recruitment.
Dextran release assays
MutuDCs were pulsed with 1 mg/ml 3000MW Tetramethylrhodamine (TRITC)-labeled dextran (Cat#D3307, ThermoFisher Scientific)
for 45 min, washed extensively, and incubated with indicated compounds for 1 h. To quantify dextran release into the cytosol, the
images were segmented using the watershed algorithm andmedian fluorescence of the all pixels within each cell was used as amea-
sure of cytosolic fluorescence.
Prazosin-BODIPY accumulation
Imaging was performed immediately after addition of 5 mM prazosin-BODIPY, 10 mg/ml BODIPY, 10 mM NH4Cl, or indicated com-
binations. Where indicated, MutuDCs were first pulsed with 10 mg/ml WGA-Alexa Fluor 647 (Cat#W32466, ThremoFisher) for 30 min
and washed extensively. For quantification of Prazosin-BODIPY accumulation the images were segmented using the watershed al-
gorithm and the number of spots per cell was quantified using the ‘‘Analyse particles’’ function.
MC38-GFP-OVA tumour growth experiments
WTmicewere injected subcutaneously with 2x106OVA-expressingMC38 cells 100 mL of cold-sterile 1x PBS.When tumours became
detectable, the animals were injected three times per week with 0.5 mg/mouse of prazosin i.p. Tumor growth was measured three
times a week and volume was calculated as (height3width2)/2 (where width is the shorter measurement). When tumor size reached
1000 mm3, the mice were euthanised.
B16-OVA tumour growth experiments
WT or NSG mice were injected subcutaneously with 2.5x105 OVA-expressing B16 cells in 100 mL of cold-sterile PBS. When tumors
became visible, usually within a week, mice were randomly assigned to different treatment groups. Injections of prazosin (0.5 mg/
mouse, i.p.) and/or anti-PD1 antibody (200 mg/mouse, i.p.) were then performed three times per week, starting the day of tumor
appearance. Vehicle (cold water and/or PBS) was injected into control mice. Tumor growth was measured three times a week
and volume was calculated as above. When tumor size reached 1000 mm3, mice were euthanized. To control for toxic effects of pra-
zosin, we performed a pilot experiment in whichmice were treated for a period of onemonth with: 0.5 g prazosin in 1ml, administered
i.p., 3x a week (total of 13 injections, total dose: 7.5 g prazosin per mouse); no adverse effects were observed.
Themean growth rate curves were estimated using loess function in R. The statistical significance analysis was performed in Prism
using ANOVA with FDR Benjamini-Hochberg correction.
Whole cell proteomics
MutuDCswere grown in SILAC light or SILAC heavy culture medium, in 15 cm dishes, to 70%–90%confluency. SILAC heavy labeled
cells were treated with tamoxifen or prazosin (20 mM) for 4 h at 37C; SILAC light labeled cells were treated with DMSO (vehicle)
only. Cells were incubated for 3h 45 min at 37C, and harvested. Cell pellets were lysed in SDS buffer (2.5% (w/V) SDS, 50 mM
Tris-HCl, pH = 8.0), and incubated at 90C for 10 min. To shear genomic DNA, lysates were passed through a QIAashredder (-
QIAGEN). Lysateswere then processed for analysis bymass spectrometry as described below. For the repeat experiment, the SILAC
labeling of control and treated cells was swapped. Protein concentrations were estimated by BCA assay. Equal amounts of control
and treated samples (i.e., SILAC light and heavy, or vice versa) were pooled, and acetone precipitated as described (Itzhak et al.,
2016). Samples were subjected to tryptic digest using the FASP method (Wisniewski et al., 2009). Peptides were fractionated into
six fractions using strong cation exchange (Kulak et al., 2014) (SCX), prior to mass spectrometric analysis.
Proteomic analysis of cytosol
MutuDCs were cultured in SILAC light or SILAC heavy growth medium, in 10 cm dishes, to 70%–90% confluency. SILAC light cells
were treated with tamoxifen, prazosin (both at 10 mM), or vehicle (DMSO) for 4 h at 37C; SILAC heavy labeled cells were left un-
treated, and served as internal reference. Treatments were performed in quadruplicate (two pairs of replicates prepared on two
different days). Cells were harvested and resuspended in STE buffer (250 mM sucrose, 0.5 mM MgCl2, 0.2 mM EGTA, 25 mM
Tris-HCl, pH = 7.5 at 4C). Aliquots of SILAC heavy labeled cells were mixed with proportional aliquots of the tamoxifen-, prazosin-
or DMSO-treated SILAC light cells. Cells were lysed mechanically in a Dounce homogenizer (tight pestle, 40 strokes, on ice). Lysates
were centrifuged at 2,000 x g for 10min at 4C, to pellet cell debris und nuclei. Post nuclear supernatants were centrifuged at 135,000
x g for 45 min at 4C to pellet organelles and microsomes. Supernatants were the cytosolic fraction. Protein concentrations were
estimated by BCA assay; aliquots were acetone precipitated and subjected to in-solution digest and stage-tip peptide cleanup as
previously described (Itzhak et al., 2016), prior to mass spectrometric analysis.e5 Cell Reports 32, 107905, July 14, 2020
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Organellar maps were prepared essentially as described (Itzhak et al., 2016), with minor modifications to the protocol. Briefly,
MutuDCs were cultured in SILAC light or SILAC heavy growth medium, in 15 cm dishes, to 70%–90% confluency. SILAC light cells
were treated with tamoxifen or prazosin (10 mM), or vehicle (DMSO), for 4 h; SILAC heavy labeled cells were treated with vehicle
(DMSO), and served as reference. Two dishes were used for each treatment (SILAC light cells), and four dishes to generate the SILAC
heavy reference. Unlike in Itzhak et al. (2016), the same reference was used for treated and control maps. Cells were harvested (with
the drugs or DMSO added to the PBS (-) cell detachment buffer), chilled on ice, lysed mechanically in STE buffer (250 mM sucrose,
0.5 mMMgCl2, 0.2 mMEGTA, 25 mM Tris-HCl, pH = 7.5 at 4C), with a Dounce homogenizer, and centrifuged at 1,000 x g for 10 min
to pellet nuclei and cell debris. Post-nuclear supernatants of SILAC light labeled cells were then subjected to a series of differential
centrifugation steps (4,000 x g for 10 min; 10,000 x g for 15 min; 20,000 x g for 20 min; 40,000 x g for 20 min; 80,000 x g for 30 min).
Post nuclear supernatant from SILAC heavy cells was centrifuged once at 80,000 x g for 30 min to obtain the reference fraction. All
pellets were resuspended in SDS buffer (2.5% (w/V) SDS, 50 mM Tris-HCl, pH = 8.0), and heated to 90C for 3 min. Protein concen-
trations were estimated by BCA assay. Equal amounts of SILAC heavy reference fraction were mixed with each SILAC light subfrac-
tion, acetone precipitated and subjected to in-solution digest and stage-tip peptide cleanup as described (Itzhak et al., 2019), prior to
mass spectrometric analysis.
Fractionations were prepared in duplicate, on two different days (six maps total – two controls, two from cells treated with tamox-
ifen, and two from cells treated with prazosin).
Mass spectrometry and data processing
Mass spectrometric analysis was performed as described (Itzhak et al., 2016), using a Thermo EASY-nLC 1000 HPLC coupled to a Q
Exactive HF Hybrid Quadrupole-Orbitrap (Thermo Fisher Scientific, Germany). HPLC gradient lengths varied for the different exper-
iments. For analysis of whole proteomes, each of the SCX peptide fractions was analyzed with a 240 min gradient (24 h per sample in
total). For the analysis of cytosol and fractions from the organellar maps, each sample was analyzed with a single 150 min gradient.
Raw files were processed with MaxQuant software Version 1.6 (Cox and Mann, 2008), using the murine reference proteome (Swiss-
Prot canonical and isoform data) database downloaded from UniProt (https://www.uniprot.org:443/).
Bioinformatic analysis of the proteomic data
Protein groups identified through MaxQuant analysis were filtered to remove reverse hits, proteins identified with modified peptides
only, as well as common contaminants. Further processing depended on the individual experiment:
Copy number estimates of proteins expressed in MutuDC
To estimate absolute protein abundance in MutuDCs, the SILAC datasets used for full proteome analysis of drug-treated cells were
used (see below). Each of the four dataset combined control cells and drug treated cells. From each dataset, the protein intensities
from the control cells were selected, to obtain four replicate full proteomes. Intensities within each replicate were summed, and all
replicates were linearly normalized to the same summed intensity. Next, only proteins detected in at least two replicates were re-
tained (7427 in total). Copy number estimates were calculated using the Proteomic Ruler (Wisniewski et al., 2014), as implemented
in Perseus software (V1.5) (Tyanova et al., 2016), and described in Itzhak et al. (2019). Protein intensities were scaled to molecular
mass.
Drug-induced changes in whole cell proteomes
For analysis of drug-induced changes in whole cell proteomes, only proteins with at least three SILAC quantification events in each of
the four experiments (2 x control versus tamoxifen, 2 x control versus prazosin) were retained (5848 proteins). SILAC ratios were lin-
early normalized to a column median of 1 in each experiment, logarithmised, and analyzed with the ‘Significance A’ tool in Perseus
software (Tyanova et al., 2016). Proteins that changed significantly in both replicate experiments with one drug (FDR = 0.05 within
each replicate, Benjamini-Hochberg correction), with a consistent direction of change, were considered as hits for this drug. Proteins
that changed significantly across both replicates and both drug treatments, with a consistent direction of change in all four measure-
ments, were considered as hits common to both drugs.
Drug-induced changes in cytosol
For analysis of drug-induced changes in cytosol, only proteins with at least three SILAC quantification events in each of the four rep-
licates were retained (2129 proteins). SILAC ratios were linearly normalized to a column median of 1 in each experiment, and loga-
rithmised. For each protein, the average ratio SILAC light/SILAC heavy from the four replicates was calculated for each condition, and
average control (DMSO) ratios were then subtracted from average treatment (tamoxifen or prazosin) ratios. Thus, for every protein,
the average change in cytosolic levels caused by either tamoxifen or prazosin relative to DMSO was obtained.
The log ratios from thewhole cell proteome and cytosol analyses were plotted against each other for each treatment (including only
proteins detected in both). To compare the distribution of lysosomal proteins with the distribution of all detected proteins, a




Generation of organellar maps and outlier testing followed the principles described in detail (Itzhak et al., 2019; 2016), with some
modifications to accommodate a comparison across three conditions. Only proteins with high quality SILAC ratios in all 30 subfrac-
tions, i.e., across all six maps, were retained (1857 proteins). (High quality SILAC ratios are those calculated from three or more quan-
tification events. In addition, ratios calculated from only two quantification events are also included in the high quality set if the cor-
respondingMaxQuant ratio variability was below 30%). Eachmap consisted of a set of five SILAC ratios for each protein, mirroring its
distribution across the differential centrifugation fractions. SILAC ratios were inverted, and divided by the sum of all five ratios across
the map. This yielded for each protein a ‘per map’ normalized profile (summing to 1). For the MutuDC control map shown in 2C and
Figures 3B, all proteins passing the high quality filter in both replicates were included (2121 proteins). To visualize themap the prcomp
function in R was used, with the following parameters: (center = TRUE, scale. = TRUE). Organellar marker proteins were initially cho-
sen from our previously published set, and augmented as described (Itzhak et al., 2016).
Subcellular localization predictions in MutuDC
Organellar maps from the two control map replicates (0-1 normalized, Data S2) were annotated with 559 markers for 12 organellar
compartments, by cross-matching our previously derived set of humanmarker proteins (Itzhak et al., 2016). Support vectormachines
(implemented in Perseus software, V1.6) (Tyanova et al., 2016) were trained to predict organellar association as described (Itzhak
et al., 2016), with an overall recall of 93% and a median F1 score of 0.88 across all compartments (Data S2).
Drug induced protein movements
To identify proteins that moved significantly and robustly, our previously reported MR (movement and reproducibility) (Itzhak et al.,
2016) analysis was applied, with minor modifications. Unlike in our previous study, here only one reference fraction was used to
generate the control and treatment maps. This reference came from cells treated with DMSO only. A different normalization was
therefore required, to allow the outlier test to detect changes in membrane association as well as organellar localization shifts. SILAC
ratios were first normalized within each fraction to a column median of 1. Next, for each protein, SILAC ratios were inverted, and
weighted with fraction yields (determined by BCA assay) (Itzhak et al., 2016). Within each map all data were then summed. This re-
flected overall amount of protein detected in each map (prep yield). The smallest prep yield was set to one, and correction factors for
the other five maps were calculated relative to this value. All data within a map were then globally normalized through division by the
prep yield correction factor. The result were six maps in which the sum of all data points is equal. Next, for each protein the ten data
points from the two tamoxifen replicates and the ten corresponding data points from control replicates were divided by the sum of all
of these ratios. The same was repeated for the ten data points from the two prazosin replicates, using the same ten control data
points. This procedure results in an additional ‘‘within treatment’’ normalization of the maps. Next, for each protein, the treatment
profiles were subtracted from the corresponding control profiles, to yield ‘delta’ profiles. For every protein, four delta profiles,
with five data points each (two sets from tamoxifen and two sets from prazosin treatment) were obtained. Delta profiles from treat-
ment replicates were combined into one profile (ten data points) and analyzed with the multivariate outlier test in Perseus software
(Perseus 1.6, 101 iterations, quantile = n*0.75) (Itzhak et al., 2016).Movement (M) scoreswere calculated as the negative log(10) of the
FDR corrected p values (Benjamini-Hochberg method). For example, an M score of four identifies significantly moving proteins with
an FDR of 0.01%. The reproducibility (R) score was calculated as the Pearson correlation of the two five-data point delta profiles
within treatment replicates. A significance cut-off corresponding to a p value of 0.05 (R = 0.8) was chosen. Since the R-score rep-
resents an additional filter, orthogonal to the M-score, further multiple hypothesis correction of the p value was not required.
Each protein with significant M (> 4) and R (> 0.8) scores was considered as shifting significantly. Thus, for every protein two sets
of M and R scores were obtained, reflecting shifts caused by tamoxifen or prazosin treatment. Each treatment produced a partially
overlapping list of shifting proteins.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details of the statistical analysis are provided in Figure Legends and in STAR Methods. Plots were generated using GraphPad Prism
version 8.4.2 for Mac (GraphPad Software, La Jolla California USA) or R (R Core Team, R: A Language and Environment for Statistical
Computing (Version 3.5.0, R Foundation for Statistical Computing, Vienna, 2018; https://www.R-project.org/) and Tidyverse (Wick-
ham et al., 2019).
ADDITIONAL RESOURCES
A web resource to mine proteomics data associated with the study is available at http://dc-biology.mrc-lmb.cam.ac.uke7 Cell Reports 32, 107905, July 14, 2020
